News Conference News ACC 2026 Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering Michael O'Riordan April 01, 2026
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for March 2026 Caitlin E. Cox April 01, 2026
News Conference News ACC 2026 PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV Michael O'Riordan March 29, 2026
News Conference News ACC 2026 Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE Yael L. Maxwell March 28, 2026
News Daily News Genomics, Lipids, Inflammation at Midlife Predict Future CAD Caitlin E. Cox March 25, 2026
News Daily News Lower LDL Levels, Starting Earlier in Life: New ACC/AHA Dyslipidemia Guidelines Michael O'Riordan March 13, 2026
News Daily News Adult Survivors of Childhood Cancer May Do Well With Simple Strategy for CV Risk Caitlin E. Cox February 13, 2026
News Conference News AHA 2025 CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia Todd Neale November 08, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Daily News AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review Todd Neale July 24, 2025
News Daily News Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests Yael L. Maxwell January 17, 2025
News Features Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s? Michael O'Riordan January 17, 2025
News Daily News Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results Michael O'Riordan December 04, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Opinion Editor's Corner Olympic Hearts: Screening for CVD Among Team USA’s Athletes Michael O'Riordan July 31, 2024
News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023